Twenty questions patients ask about drug-resistant epilepsy and treatment in China

Drug-resistant epilepsy decisions can involve several specialties. Patients do not need to master every technical term before a consultation. Clarifying the questions that affect the next decision helps explain why a clinician recommends a particular assessment or treatment. These twenty answers draw on professional guidance, original research, and official Chinese information checked through September 9, 2026.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The team needs to establish whether each schedule was appropriate, adequately used, tolerated, and actually followed. The core definition generally concerns failure of two schedules meeting those conditions to achieve sustained seizure freedom. Counting medicine names or years of illness is insufficient. Record the period of use, benefit, reason for stopping, and any supply interruption. This allows the clinician to distinguish an unsuccessful adequate treatment from an incomplete trial and identify practical problems that may still be addressed. Bring the actual treatment history rather than trying to assign the label yourself. ILAE: Drug-Resistant Epilepsy, definition and clinical resources NICE NG217: Terms used, drug-resistant epilepsy definition, updated January 2025
That should not be the expectation. Neurostimulation requires programming and continuing evaluation and is often used with medication. A frequency reduction reported in long-term studies is not equivalent to complete seizure freedom for all recipients or a guaranteed withdrawal date. Before treatment, clarify device suitability, support requirements, and actual use conditions in China. International patients should identify who can manage the system after they return home. Implantation alone does not create a sustainable treatment plan if essential checks and programming cannot be obtained. The maintenance commitment belongs in the decision from the outset. NINDS: Deep Brain Stimulation Nair et al.: Nine-year prospective brain-responsive neurostimulation outcomes, Neurology 2020
For prolonged convulsions, repeated seizures without recovery, abnormal breathing, or serious injury, follow the individual rescue plan and seek local emergency help immediately. Do not wait for a cross-border reply. Once the person is stable, provide the event description, active treatment, and recent changes to the responsible clinicians for review. Before discharge, identify the home clinician, medication supply route, pending results, and formal Chinese team contact. Clear responsibilities help distinguish an emergency response from a later consultation about causes and treatment changes, allowing both to happen at the appropriate time. CDC: First Aid for Seizures NICE NG217: Treating status epilepticus, repeated or cluster seizures, and prolonged seizures Oxford University Hospitals: After epilepsy surgery

Quick answer

Full guide

1. Does having tried many medicines prove that my epilepsy is drug-resistant?

The team needs to establish whether each schedule was appropriate, adequately used, tolerated, and actually followed. The core definition generally concerns failure of two schedules meeting those conditions to achieve sustained seizure freedom. Counting medicine names or years of illness is insufficient. Record the period of use, benefit, reason for stopping, and any supply interruption. This allows the clinician to distinguish an unsuccessful adequate treatment from an incomplete trial and identify practical problems that may still be addressed. Bring the actual treatment history rather than trying to assign the label yourself. ILAE: Drug-Resistant Epilepsy, definition and clinical resources NICE NG217: Terms used, drug-resistant epilepsy definition, updated January 2025

2. Should I wait several more years before seeking specialist assessment?

A fixed additional waiting period is generally not the purpose of the referral process. ILAE guidance supports timely consideration of surgical evaluation so that the full range of options can be assessed; referral does not mean that everyone proceeds to an operation. Medication optimization can continue meanwhile. Ask whether a comprehensive assessment has already occurred and, if not, what is missing: localization, functional risk assessment, or a discussion involving the relevant disciplines. Identifying that gap gives the next step a clearer purpose than simply repeating another medicine change without reviewing the wider pathway. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

3. If MRI shows no lesion, are other options ruled out?

No. MRI technique, image quality, and review by specialists using the clinical history all affect interpretation. Some patients require additional integration with EEG or functional imaging, but this does not mean that every advanced test should be ordered. A negative MRI alone should not close consideration of surgical evaluation. Retain original images and the report and ask what clinical question any proposed new study will answer. An expert review may clarify whether existing images are adequate or whether a targeted new acquisition is justified. The words no abnormality on one report are not a complete treatment decision. Bernasconi et al.: ILAE structural MRI recommendations and HARNESS protocol, 2019 Traub-Weidinger et al.: EANM PET and SPECT practice guideline for epilepsy, 2024

4. Why can epilepsy remain possible when the EEG is normal?

A routine EEG samples a limited period. Failure to record an abnormality does not exclude epilepsy, which is assessed using the event history, observations, videos, and appropriate investigations. Conversely, abnormal discharges do not automatically explain every type of spell. Tell the clinician whether the usual event occurred during recording and what medication and sleep circumstances applied. Further monitoring may be selected to answer a particular question. The aim is not to repeat the same test until it produces a preferred result, but to gather evidence that can resolve the diagnostic uncertainty. NICE NG217: Diagnosis and assessment of epilepsy Tatum et al.: ILAE/IFCN minimum standards for inpatient long-term video-EEG, Epilepsia 2022

5. Does a medicine I could not tolerate count as ineffective?

Poor tolerability and lack of seizure control despite adequate use need separate documentation. A serious reaction may prevent completion of a trial and can strongly influence the next choice, but the record should not compress every experience into did not work. Describe the symptoms, timing, medical assessment, and changes after treatment was adjusted. New serious skin symptoms, systemic illness, or altered awareness need prompt assessment. Do not persist through a potentially severe reaction to prove that a trial was adequate, and do not deliberately take a suspected offending medicine again to test an allergy. NICE NG217: Principles of treatment, safety, monitoring and withdrawal FDA safety communication: DRESS with levetiracetam and clobazam, November 2023

6. Does a genetic finding always lead to a matching precision treatment?

No. A result may be pathogenic, likely pathogenic, or of uncertain significance, and the mechanism of a particular variant can matter. A gene name alone is not enough to select treatment or establish access to an investigational drug. Bring the full laboratory report and subsequent updates for interpretation alongside the syndrome and clinical features. Family testing or reanalysis may be useful when it addresses a specific question. Do not change an uncertain result into a confirmed diagnosis in a translation or summary to match an advertised therapy or a trial requirement. Krey et al.: Current practice in diagnostic genetic testing of the epilepsies, ILAE Genetics Commission, 2022

7. Does a diagnosis of functional seizures mean the clinician thinks I am pretending?

No. Functional seizures are real symptoms that require appropriate care, and they can coexist with epilepsy. The diagnosis needs positive clinical evidence and suitable assessment; one normal EEG alone is not enough. Treatment should distinguish the event types. Antiseizure medicines do not generally directly treat functional seizures themselves, while coexisting epilepsy may still require medication. Ask the team to explain the evidence and the separate care plans. Keeping the events distinct also prevents confusion when judging whether an epilepsy treatment has changed the frequency of the relevant seizures. AAN: Management of Functional Seizures, clinical guideline summary, December 2025

8. Does agreeing to a surgical evaluation commit me to an operation?

It does not. Evaluation may identify a treatable focal origin, or it may show that evidence is insufficient, functional risk is too high, or another approach is more appropriate. Patients should understand the target, possible benefit, memory or language risks, and alternatives before consenting to a procedure. Even when surgery is not recommended, assessment may improve understanding of the diagnosis or medication strategy. The useful outcome is a clear conclusion and next step. A planned sequence of appointments should not create pressure to undergo an operation simply because the evaluation has already begun. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022 Baxendale et al.: ILAE neuropsychological assessment in epilepsy surgery, 2019

9. Is SEEG a minimally invasive cure for epilepsy?

Stereo-EEG primarily records intracranial electrical activity to investigate seizure origin. Electrode sampling follows a specific hypothesis and cannot observe every potential starting point throughout the brain. Thermocoagulation or another treatment may be considered in selected circumstances after interpreting the recordings and functional risks. SEEG is invasive and is not required for every patient; it does not guarantee a later resection. Ask about the localization question, procedural risks, and the actions that different findings could support. This separates the purpose of the diagnostic stage from a treatment that may or may not follow. UCLH: A guide for patients considering epilepsy surgery Cockle et al.: Language mapping and decline after SEEG radiofrequency thermocoagulation, Brain 2025

10. Are laser or robot-assisted approaches always better than conventional surgery?

Different technologies address different clinical situations. Incision size or a technical label cannot establish overall superiority. Laser ablation has a particular evidence base and eligibility context, while robotic assistance may support aspects of planning or execution; neither removes functional risk. The relevant comparison is how each suitable option addresses the person's seizure origin, expected outcome, risks, and possible later treatment. A 2025 laser registry provides follow-up in a defined population, but is not a randomized demonstration of superiority over open surgery for every patient. Ask for the reasoning that applies to your findings. Interstitial Thermal Therapy in Mesial Temporal Lobe Epilepsy, prospective LAANTERN registry, JAMA Neurology 2025

11. Can medication stop immediately after a stimulator is implanted?

That should not be the expectation. Neurostimulation requires programming and continuing evaluation and is often used with medication. A frequency reduction reported in long-term studies is not equivalent to complete seizure freedom for all recipients or a guaranteed withdrawal date. Before treatment, clarify device suitability, support requirements, and actual use conditions in China. International patients should identify who can manage the system after they return home. Implantation alone does not create a sustainable treatment plan if essential checks and programming cannot be obtained. The maintenance commitment belongs in the decision from the outset. NINDS: Deep Brain Stimulation Nair et al.: Nine-year prospective brain-responsive neurostimulation outcomes, Neurology 2020

12. Is it still accurate in 2026 to describe cenobamate as unapproved in China?

The developer's official Chinese product information states that cenobamate tablets received Chinese approval in 2025 for adult partial-onset seizures. Older statements that it remains unapproved in China should therefore not be repeated without updating. Suitability, access, and payment still require confirmation with the hospital. Current overseas labeling contains significant safety warnings, while an actual Chinese prescription should be checked against the formal local product information and individual monitoring needs. Approval does not make a medicine something to substitute independently on the strength of a news report or another patient's experience. 翼思生物官方产品资料：西诺氨酯2025年在中国获批成人部分性发作适应证 DailyMed: XCOPRI U.S. prescribing information, revised August 2025, current retrieval September 2026

13. Are the newest cell or gene-related approaches already routine treatments?

Research progress and routine authorized treatment remain different stages. Rezanecel is one example: early research attracted attention, but UCB's July 2026 update placed planned phase 3 initiation in the first half of 2027. Early findings or a development designation should not be presented as marketing approval. Candidates also differ in the syndromes, ages, and mechanisms studied. When considering research, obtain the study identifier, confirmation from the center, and formal consent information covering screening, risks, costs, and continuing care. A headline is not a sufficient basis for booking a treatment visit. UCB: Half-year update July 30, 2026, rezanecel phase 3 now planned for H1 2027 NIH: Clinical research and trials, the basics for participants

14. Can I start a ketogenic diet using an online recipe?

Therapeutic ketogenic dietary treatment requires assessment, an individualized prescription, and follow-up, with particular attention to nutrition, growth, and tolerability in children. It is not equivalent to a weight-loss diet, and medicines and other illnesses can influence suitability. Agree with the team on goals, monitoring, and what to do if vomiting or inadequate intake occurs. Adults also need professional support. Describe food access, school arrangements, and caregiver capacity before deciding. These practical factors help the dietitian design a plan that can be carried out safely beyond the specialist clinic. Schoeler et al.: International dietetic best practice for ketogenic dietary therapies in children and young people, 2025 Cervenka et al.: International recommendations for adults treated with ketogenic diet therapies, 2021

15. Should I tolerate worse sleepiness or irritability if seizures have improved?

Report those changes because alertness, mood, and everyday function are also treatment outcomes. Record when they began, their relationship to adjustments, and what they prevent the person from doing. Sleep, seizures, and other conditions may contribute, so the cause should not be assigned from timing alone. Do not test the explanation by independently omitting treatment. A prospective study published in 2026 links depression-related factors with quality of life in drug-resistant focal epilepsy. Suicidal risk, difficulty waking, or abnormal breathing requires urgent help rather than waiting for an ordinary medication review. Mula et al.: Drug-treatment changes, depression and quality of life in adult drug-resistant focal epilepsy, Epilepsia July 2026 DailyMed: Levetiracetam prescribing information, February 2026

16. How can I judge whether a high success rate applies to me?

Ask what success means, who was studied, how long follow-up lasted, and whether incomplete follow-up affects the denominator. Complete freedom from seizures and auras differs from auras only, freedom from disabling events, or a reduction in frequency. A group result cannot simply become a personal probability. Ask the clinician to explain expectations and uncertainty using your cause, localization, and functional situation, and to describe reassessment if the goal is not reached. This provides a more useful basis for consent than an impressive number without a population or outcome definition. Wieser et al.: ILAE classification of outcome following epilepsy surgery, 2001 Nair et al.: Nine-year prospective brain-responsive neurostimulation outcomes, Neurology 2020

17. May I stop medication after two seizure-free years following surgery?

Two years without seizures can be a point for individualized risk discussion, not an automatic stop date. A 2026 observational study of adults after resective surgery associated earlier withdrawal with greater early relapse risk; it was not a randomized withdrawal timetable for everyone. Cause, postoperative events, treatment burden, and the consequences of recurrence still matter. If a reduction is appropriate, the responsible clinician should provide written steps and a response plan. Do not discontinue several medicines together independently or apply adult resection findings directly to a child or a different intervention. AAN: Antiseizure medication withdrawal in seizure-free patients, practice advisory update, 2021 Ferreira-Atuesta et al.: Timing of antiseizure medication withdrawal after adult epilepsy surgery, multicenter observational study, Neurology 2026

18. Is there a standard all-inclusive price for epilepsy care in China?

Without adequate records and a defined pathway, an individual total cannot be estimated credibly. Video-EEG, SEEG, resection, ablation, and implantation involve different resources and follow-up. National service categories do not establish one total price across China, and DRG/DIP version 3.0 payment standards are not an automatic cap on a patient's own spending. Request a staged estimate with clear inclusions and exclusions, then verify personal benefits with the relevant insurer or insurance administration. Do not subtract an unconfirmed reimbursement from the money available for care. Direct billing also has coverage limits. 国家医保局：神经系统类医疗服务价格项目立项指南（试行）编制说明，2025 国家医保局：按病种付费3.0版新闻发布会实录，2026年9月2日北京协和医院国际医疗部：商业保险常见问题及直付边界

19. What should be checked first when choosing a Chinese hospital and planning travel?

Confirm that the service accepts the patient's age, syndrome, and current problem, and verify the necessary assessment and multidisciplinary capabilities through official channels. The China Association Against Epilepsy map can help locate services but does not replace the hospital's acceptance of the case. Submit a summary, treatment history, and original imaging before committing to the visit, and explain travel and caregiving constraints. The existing clinician should assess travel-related concerns and the carrier's requirements should be checked. Having a ticket or appointment is not medical clearance. 中国抗癫痫协会官方网站及CAAE癫痫地图入口 UK Civil Aviation Authority: Neurology guidance for airline passengers, current retrieval September 2026

20. If a seizure occurs after returning home, should I contact China first or seek emergency care?

For prolonged convulsions, repeated seizures without recovery, abnormal breathing, or serious injury, follow the individual rescue plan and seek local emergency help immediately. Do not wait for a cross-border reply. Once the person is stable, provide the event description, active treatment, and recent changes to the responsible clinicians for review. Before discharge, identify the home clinician, medication supply route, pending results, and formal Chinese team contact. Clear responsibilities help distinguish an emergency response from a later consultation about causes and treatment changes, allowing both to happen at the appropriate time. CDC: First Aid for Seizures NICE NG217: Treating status epilepticus, repeated or cluster seizures, and prolonged seizures Oxford University Hospitals: After epilepsy surgery